SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of May 2017
Commission File Number: 001-36349
MediWound Ltd.
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY NOTE
On May 8, 2017, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Reports First Quarter 2017 Financial Results”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.
In addition, pursuant to the Information Rights Agreement between the Company and Clal Biotechnology Industries Ltd. ("CBI"), dated March 3, 2014 (which was attached to the Company's registration statement as exhibit 4.3), the Company is required to provide CBI with certain information necessary for CBI to meet its obligations under Israeli Securities Law. This Form 6-K includes an Un-Audited Interim Financial Statements as of March 31, 2017, attached as Exhibit 99.2, which was provided by the Company to CBI on May 7, 2017 pursuant to such contractual obligation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MEDIWOUND LTD.
|
|
Date: May 8, 2017
|
By:
|
/s/ Sharon Malka
|
|
|
Name:
|
Sharon Malka
|
|
|
Title:
|
Chief Financial Officer
|
|
EXHIBIT INDEX
The following exhibit is filed as part of this Form 6-K:
Exhibit
|
Description
|
|
|
99.1
|
Press release dated May 8, 2017 titled “MediWound Reports First Quarter 2017 Financial Results”.
|
|
|
99.2
|
Un-Audited Interim Financial Statements as of March 31, 2017.
|